Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program

DESTINY-Breast05 and DESTINY-Breast11 examined distinct early breast cancer populations to better understand how novel HER2-targeted therapies may improve outcomes. DESTINY-Breast05 focused on patients with high-risk, residual disease after neoadjuvant therapy, while DESTINY-Breast11 explored treatment in the preoperative setting, evaluating how these agents may enhance pathologic response. In the metastatic setting, DESTINY-Breast09 studied patients with previously untreated HER2-positive metastatic breast cancer to assess the role of antibody-drug conjugates earlier in the disease course. Examining these specific populations is essential because each group faces unique prognostic challenges and therapeutic needs.